covid - 19患者的药物治疗:相互作用和适应症

Mercedes Iglesias , Eva Benavent , Óscar Murillo , José Luis Ferreiro
{"title":"covid - 19患者的药物治疗:相互作用和适应症","authors":"Mercedes Iglesias ,&nbsp;Eva Benavent ,&nbsp;Óscar Murillo ,&nbsp;José Luis Ferreiro","doi":"10.1016/S1131-3587(20)30033-9","DOIUrl":null,"url":null,"abstract":"<div><p>The search for effective treatments against COVID-19 in the current pandemic has presented the scientific community with an enormous challenge. In fact, there is still no effective treatment for SARS-CoV-2 infection, apart from supportive measures. Research has focused on re-examining antiviral drugs that were previously used against other viral infections and on the use of anti-inflammatories, since COVID-19 patients can develop a hyperinflammatory state, which is associated with a poorer disease prognosis. However, these drugs, sometimes administered on a compassionate-use basis, can cause serious side effects or drug interactions that we should be aware of. The aim of this article is to provide an overview of what is currently known about the pharmacological therapies most frequently used against COVID-19 in our field, while paying particular attention to the adverse events and drug interactions that can affect the cardiovascular system.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30033-9","citationCount":"2","resultStr":"{\"title\":\"Tratamientos farmacológicos de los pacientes con COVID19: interacciones e indicaciones\",\"authors\":\"Mercedes Iglesias ,&nbsp;Eva Benavent ,&nbsp;Óscar Murillo ,&nbsp;José Luis Ferreiro\",\"doi\":\"10.1016/S1131-3587(20)30033-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The search for effective treatments against COVID-19 in the current pandemic has presented the scientific community with an enormous challenge. In fact, there is still no effective treatment for SARS-CoV-2 infection, apart from supportive measures. Research has focused on re-examining antiviral drugs that were previously used against other viral infections and on the use of anti-inflammatories, since COVID-19 patients can develop a hyperinflammatory state, which is associated with a poorer disease prognosis. However, these drugs, sometimes administered on a compassionate-use basis, can cause serious side effects or drug interactions that we should be aware of. The aim of this article is to provide an overview of what is currently known about the pharmacological therapies most frequently used against COVID-19 in our field, while paying particular attention to the adverse events and drug interactions that can affect the cardiovascular system.</p></div>\",\"PeriodicalId\":34926,\"journal\":{\"name\":\"Revista Espanola de Cardiologia Suplementos\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30033-9\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola de Cardiologia Suplementos\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1131358720300339\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1131358720300339","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

摘要

在当前的大流行中,寻找有效的治疗方法给科学界带来了巨大的挑战。事实上,除了支持性措施外,目前还没有有效的治疗方法。研究的重点是重新检查以前用于治疗其他病毒感染的抗病毒药物和抗炎药的使用,因为COVID-19患者可能出现高炎症状态,这与疾病预后较差有关。然而,这些药物,有时在同情使用的基础上,可能会导致严重的副作用或药物相互作用,我们应该意识到。本文的目的是概述目前已知的在我们的领域最常用的针对COVID-19的药物治疗,同时特别关注可能影响心血管系统的不良事件和药物相互作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Tratamientos farmacológicos de los pacientes con COVID19: interacciones e indicaciones

The search for effective treatments against COVID-19 in the current pandemic has presented the scientific community with an enormous challenge. In fact, there is still no effective treatment for SARS-CoV-2 infection, apart from supportive measures. Research has focused on re-examining antiviral drugs that were previously used against other viral infections and on the use of anti-inflammatories, since COVID-19 patients can develop a hyperinflammatory state, which is associated with a poorer disease prognosis. However, these drugs, sometimes administered on a compassionate-use basis, can cause serious side effects or drug interactions that we should be aware of. The aim of this article is to provide an overview of what is currently known about the pharmacological therapies most frequently used against COVID-19 in our field, while paying particular attention to the adverse events and drug interactions that can affect the cardiovascular system.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista Espanola de Cardiologia Suplementos
Revista Espanola de Cardiologia Suplementos Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.20
自引率
0.00%
发文量
1
期刊介绍: Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.
期刊最新文献
Riesgo residual. Conclusiones Consideraciones clínicas y estrategias terapéuticas para reducir el riesgo residual Icosapento de etilo en la disminución del riesgo residual. Nuevas evidencias Recomendaciones actuales de las guías respecto al riesgo residual ¿Qué es el riesgo cardiovascular residual? Etiología, lípidos e inflamación
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1